Latest Breaking News On - டேனியல் ஆத்மா - Page 1 : comparemela.com

MASSENA — St. Lawrence Health System’s Clinical and Rural Health Research Department was selected in September 2020 to be part of the COVID-19 ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. The trial has been underway at Canton-Potsdam Hospital, and has expanded to Massena Hospital, with oversight provided by Massena Hospital Chief of Medicine Birinder Singh, MD, FRCPC. “ACTIV-2 is designed to help us rapidly identify treatments that have the potential to radically alter the current pandemic, and make a profound difference in the lives of people who have mild to moderate COVID-19,” stated Infectious Diseases provider Daniel Soule, DO. While initial treatments are offered primarily at the Massena location, some Potsdam appointments may be available upon request. Trial participation requires patients to have follow-up appointments, which can be conducted at either location.

Carly lovelettBirinder singhDaniel souleLawrence health system clinicalNational institute of allergyNational institutes of healthClinical researchRural health research departmentLawrence health systemMonoclonal antibodiesCanton potsdam hospitalMassena hospitalMassena hospital chiefMedicine birinder singhInfectious diseasesClinical research director carly lovelett